AVITA Medical's (RCEL) "Buy" Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of AVITA Medical (NASDAQ:RCEL - Free Report) in a report released on Wednesday,Benzinga reports. They currently have a $25.00 target price on the stock.

RCEL has been the subject of a number of other research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $21.00 price target on shares of AVITA Medical in a research report on Tuesday, December 24th. Piper Sandler reiterated a "neutral" rating and set a $12.00 target price (up from $9.00) on shares of AVITA Medical in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, AVITA Medical currently has an average rating of "Moderate Buy" and a consensus price target of $18.00.

AVITA Medical Stock Down 36.4 %

RCEL traded down $5.12 during trading on Wednesday, reaching $8.94. 1,372,330 shares of the stock traded hands, compared to its average volume of 383,039. The stock's 50-day simple moving average is $12.53 and its two-hundred day simple moving average is $10.59. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.73 and a quick ratio of 3.37. AVITA Medical has a fifty-two week low of $7.51 and a fifty-two week high of $18.93. The stock has a market cap of $234.39 million, a price-to-earnings ratio of -4.01 and a beta of 1.58.

AVITA Medical (NASDAQ:RCEL - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.21). The firm had revenue of $19.55 million during the quarter, compared to the consensus estimate of $19.65 million. AVITA Medical had a negative net margin of 95.47% and a negative return on equity of 194.69%. During the same period in the previous year, the firm posted ($0.34) EPS. As a group, equities research analysts expect that AVITA Medical will post -2.35 EPS for the current year.

Institutional Trading of AVITA Medical

Hedge funds have recently modified their holdings of the stock. FMR LLC boosted its stake in AVITA Medical by 126.9% in the third quarter. FMR LLC now owns 4,248 shares of the company's stock valued at $46,000 after acquiring an additional 2,376 shares during the last quarter. Huntington National Bank acquired a new position in shares of AVITA Medical in the 3rd quarter valued at $32,000. Rhumbline Advisers boosted its position in shares of AVITA Medical by 13.9% in the 2nd quarter. Rhumbline Advisers now owns 36,530 shares of the company's stock worth $289,000 after purchasing an additional 4,463 shares during the last quarter. Quest Partners LLC grew its stake in shares of AVITA Medical by 269.4% during the third quarter. Quest Partners LLC now owns 7,520 shares of the company's stock worth $81,000 after purchasing an additional 5,484 shares during the period. Finally, IHT Wealth Management LLC increased its holdings in AVITA Medical by 24.3% in the third quarter. IHT Wealth Management LLC now owns 28,100 shares of the company's stock valued at $301,000 after purchasing an additional 5,500 shares during the last quarter. 27.66% of the stock is owned by institutional investors.

About AVITA Medical

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.